Pacific Shuanglin Bio-pharmacy

Company Deals

Pacific Shuanglin’s Controlling Stake Transferred to CNBG in RMB 4.7B Deal

Fineline Cube Oct 15, 2025

Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE: 000403), a China-based blood products company, announced that its...

Company Deals

Pacific Shuanglin Bio-pharmacy Partners with XtalPi for Blood Product Innovation

Fineline Cube Mar 31, 2025

China-based Pacific Shuanglin Bio-pharmacy Co., Ltd (SHE: 000403) has formed a strategic partnership with Shenzhen-based...

Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Company Drug

Pierre Fabre Secures European Commission Approval for Braftovi Combination in BRAF-Mutant Colorectal Cancer

Company Drug

Hengrui’s Rezvilutamide Receives EMA Acceptance for Metastatic Prostate Cancer Treatment

Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline